Search - tctmd.com

Displaying 241 - 260 of 659

Sort: Relevancy | Date

Ticagrelor Risky in Diabetic Patients With Stable CAD: THEMIS

News Conference News ESC 2019

Ticagrelor Risky in Diabetic Patients With Stable CAD: THEMIS

Michael O'Riordan

September 01, 2019

COMPLETE Beats Culprit-Only PCI in Multivessel STEMI and Timing Doesn’t Matter

News Conference News ESC 2019

COMPLETE Beats Culprit-Only PCI in Multivessel STEMI and Timing Doesn’t Matter

Yael L. Maxwell

September 01, 2019

POPULAR AGE Supports Clopidogrel Over Ticagrelor in Elderly ACS Patients

News Conference News ESC 2019

POPULAR AGE Supports Clopidogrel Over Ticagrelor in Elderly ACS Patients

Michael O'Riordan

August 31, 2019

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

News Daily News

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Michael O'Riordan

August 26, 2019

Stroke After PCI: Rare but Rising as Patient Complexity Climbs

News Daily News

Stroke After PCI: Rare but Rising as Patient Complexity Climbs

August 05, 2019

DOACs Good for Secondary Prevention in Older A-fib Patients, Real-world Numbers Affirm

News Daily News

DOACs Good for Secondary Prevention in Older A-fib Patients, Real-world Numbers Affirm

July 23, 2019

Clopidogrel-Aspirin in Minor Stroke/TIA of Maximum Benefit in First 21 Days

News Daily News

Clopidogrel-Aspirin in Minor Stroke/TIA of Maximum Benefit in First 21 Days

July 09, 2019

Multiple Passes During Stroke Thrombectomy Ups Risk of Blood-Brain Barrier Disruption

News Daily News

Multiple Passes During Stroke Thrombectomy Ups Risk of Blood-Brain Barrier Disruption

Alison Palkhivala

July 05, 2019

Which ASCVD Patients Will Benefit Most From Rivaroxaban Plus Aspirin? Some Clues

News Daily News

Which ASCVD Patients Will Benefit Most From Rivaroxaban Plus Aspirin? Some Clues

June 26, 2019

Ischemic Events Worsen Long-term Cognitive Decline

News Daily News

Ischemic Events Worsen Long-term Cognitive Decline

Yael L. Maxwell

June 18, 2019

Absence of FH Diagnosis Linked to Increased Risk of Premature Mortality

News Conference News EAS 2019

Absence of FH Diagnosis Linked to Increased Risk of Premature Mortality

Michael O'Riordan

June 05, 2019

Bariatric Surgery Linked to Survival Advantage After MI and CVA

News Daily News

Bariatric Surgery Linked to Survival Advantage After MI and CVA

Michael O'Riordan

May 13, 2019

PFO Compounds Ischemic Stroke Risk Among Patients With Pulmonary Embolism

News Daily News

PFO Compounds Ischemic Stroke Risk Among Patients With Pulmonary Embolism

Yael L. Maxwell

May 06, 2019

News Industry News

Medtronic Announces U.S. Commercial Launch of Solitaire(TM) X Revascularization Device

April 30, 2019

Most STEMI Patients Head to ICU After PCI, but Not All Need to Go

News Daily News

Most STEMI Patients Head to ICU After PCI, but Not All Need to Go

Michael O'Riordan

April 15, 2019

New Genetic Evidence Shows Alcoholic Drinks Don’t Cut Stroke Risk

News Daily News

New Genetic Evidence Shows Alcoholic Drinks Don’t Cut Stroke Risk

Yael L. Maxwell

April 09, 2019

Ultrasound-Enhanced Thrombolysis No Help in Stroke: CLOTBUST-ER

News Daily News

Ultrasound-Enhanced Thrombolysis No Help in Stroke: CLOTBUST-ER

April 04, 2019

First US Consensus Statement on PFO Closure Addresses Volume Requirements, Quality Measurements

News Daily News

First US Consensus Statement on PFO Closure Addresses Volume Requirements, Quality Measurements

Yael L. Maxwell

April 01, 2019

CMSCoverage Plan Keeps Volume Requirements for Existing TAVR Programs but Lowers Bar for New Centers

News Daily News

CMS Coverage Plan Keeps Volume Requirements for Existing TAVR Programs but Lowers Bar for New Centers

Michael O'Riordan

March 27, 2019

AUGUSTUS: Apixaban Plus P2Y12 Inhibitor the Best Combo in A-fib Patients With ACS or Undergoing PCI

News Conference News ACC 2019

AUGUSTUS: Apixaban Plus P2Y12 Inhibitor the Best Combo in A-fib Patients With ACS or Undergoing PCI

March 17, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.